Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
How do you decide when to order blood-based biomarker testing for Alzheimer's disease and which one to choose?
Do you do it in place of CSF testing?
Related Questions
How do stroke-risk considerations affect your use of atypical antipsychotics for patients with dementia?
What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?
What would be your approach to the consideration of the use of antiamyloid monoclonal antibodies for nonamnestic Alzheimer's disease with a positive biomarker for brain amyloid pathology?
Is there sufficient evidence yet to support the use of lithium supplementation or prescription in the management of neurodegenerative diseases?
How do you utilize FDG PET in the evaluation of dementias?
How do you counsel women post-natural menopause who are interested in HRT for reducing dementia risk?
Do you recommend routine neurosyphilis testing in patients being evaluated for dementia?
How do you manage problematic disinhibited behaviors in patients with neurocognitive disorders?
What are the limits and standalone value of volumetric MRI for the preclinical evaluation of dementia?
What is your approach to Tardive Dyskinesia when VMAT2 inhibitors are ineffective or unaffordable?
